Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-07-10
2004-03-23
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S118000
Reexamination Certificate
active
06710055
ABSTRACT:
DESCRIPTION OF THE INVENTION
The present invention relates to new disubstituted bicyclic heterocycles of general formula
R
a
—A—Het—B—Ar—E (I)
the tautomers, stereoisomers and mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases which have valuable properties.
The compounds of general formula I above wherein E denotes a cyano group are valuable intermediates for preparing the other compounds of general formula I, and the compounds of general formula I above wherein E denotes an R
b
NH—C(═NH)— group, and the tautomers and stereoisomers thereof have useful pharmacological properties, particularly a thrombin-inhibiting activity and the effect of extending thrombin time.
The present application thus relates to the new compounds of general formula I above and the preparation thereof, pharmaceutical compositions containing the pharmacologically active compounds and the use thereof.
In the above general formula:
A denotes a carbonyl or sulfonyl group linked to the benzo, pyrido, pyrimido, pyrazino, pyridazino or thieno moiety of the group Het, whilst moreover the abovementioned moieties may not contain an R
1
group,
B denotes an ethylene group, wherein a methylene group, linked either to the group Het or Ar, may be replaced by an oxygen or sulfur atom or by a sulfinyl, sulfonyl, carbonyl or —NR
1
group, wherein
R
1
denotes a hydrogen atom or a C
1-6
-alkyl group,
E denotes a cyano or R
b
NH—C(═NH)— group wherein
R
b
denotes a hydrogen atom, a hydroxy group, a C
1-3
-alkyl group or a group which may be cleaved in vivo,
Ar denotes a phenylene or naphthylene group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C
1-3
-alkyl, or C
1-3
-alkoxy group,
a thienylene, thiazolylene, pyridinylene, pyrimidinylene, pyrazinylene or pyridazinylene group optionally substituted in the carbon skeleton by a C
1-3
-alkyl group,
Het denotes a bicyclic heterocycle of formula
wherein
X is a nitrogen atom and
Y is an oxygen or sulfur atom or a nitrogen atom optionally substituted by a C
1-6
-alkyl or C
3-7
-cycloalkyl group, whilst additionally one or two non-angular methyne groups in the phenyl moiety of the above-mentioned bicyclic heterocycle may each be replaced by a nitrogen atom,
or X denotes a methyne group optionally substituted by the group R
1
, wherein R
1
is as hereinbefore defined, and
Y denotes a nitrogen atom optionally substituted by a C
1-6
-alkyl or C
3-7
-cycloalkyl group,
or Het denotes a group of the formula
R
1
is as hereinbefore defined,
Z denotes an oxygen or sulfur atom,
one of the groups D or G denotes a nitrogen atom and the other group D or G denotes a methyne group,
and R
a
denotes a C
1-6
-alkyl group, a C
3-7
-cycloalkyl group optionally substituted by a C
1-3
-alkyl group, wherein the C
1-3
-alkyl group may additionally be substituted by a carboxyl group or by a group which may be converted in vivo into a carboxy group,
or an R
2
NR
3
— group wherein
R
2
denotes a C
1-4
-alkyl group, which may be substituted by a carboxy, C
1-6
-alkyloxycarbonyl, benzyloxycarbonyl, C
1-3
-alkylsulfonylaminocarbonyl, phenylsulfonylaminocarbonyl, trifluorosulfonylamino, trifluorosulfonylaminocarbonyl or 1H-tetrazolyl group,
a C
2-4
-alkyl group substituted by a hydroxy, phenyl-C
1-3
-alkoxy, carboxy-C
1-3
-alkylamino, C
1-3
-alkoxycarbonyl-C
1-3
-alkylamino, N—(C
1-3
-alkyl)-carboxy-C
1-3
-alkylamino or N—(C
1-3
-alkyl)-C
1-3
-alkoxycarbonyl-C
1-3
-alkylamino group, whilst in the abovementioned groups the carbon atom in the a-position relative to the adjacent nitrogen atom may not be substituted, or
a piperidinyl group optionally substituted by a C
1-3
-alkyl group and
R
3
denotes a hydrogen atom, a C
1-6
-alkyl group, a C
3-7
-cycloalkyl group optionally substituted by a C
1-3
-alkyl group, a C
3-6
-alkenyl or alkynyl group, wherein the unsaturated part may not be linked directly to the nitrogen atom of the R
2
NR
3
-group,
a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a C
1-3
-alkyl or C
1-3
-alkoxy group, a benzyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, thienyl or imidazolyl group or
R
2
and R
3
together with the nitrogen atom between them denote a 5- to 7-membered cycloalkyleneimino group, optionally substituted by a carboxymethyl or C
1-4
-alkoxycarbonyl group, onto which a phenyl ring may additionally be fused.
The compounds of the above general formula I which contain a group capable of being cleaved in vivo are thus prodrugs and compounds of general formula I which contain two groups capable of being cleaved in vivo are so-called double prodrugs.
The phrase “a group which may be converted in vivo into a carboxy group” denotes, for example, a hydroxymethyl group, a carboxy group esterified with an alcohol, in which the alcoholic moiety is preferably a C
1-6
-alkanol, a phenyl-C
1-3
-alkanol, a C
3-9
-cycloalkanol, wherein a C
5-8
-cycloalkanol may additionally be substituted by one or two C
1-3
-alkyl groups, a C
5-8
-cycloalkanol, in which a methylene group in the 3- or 4-position is replaced by an oxygen atom or by an imino group optionally substituted by a C
1-3
-alkyl, phenyl-C
1-3
-alkyl, phenyl-C
1-3
-alkoxycarbonyl or C
2-6
-alkanoyl group, and the cycloalkanol moiety may additionally be substituted by one or two C
1-3
-alkyl groups, a C
4-7
-cycloalkenol, a C
3-5
-alkenol, a phenyl-C
3-5
-alkenol, a C
3-5
-alkynol or phenyl-C
3-5
-alkynol, with the proviso that no bond to the oxygen atom emanates from a carbon atom which carries a double or triple bond, a C
3-8
-cycloalkyl-C
1-3
-alkanol, a bicycloalkanol having a total of 8 to 10 carbon atoms, which may additionally be substituted in the bicycloalkyl moiety by one or two C
1-3
-alkyl groups, a 1,3-dihydro-3-oxo-1-isobenzofuranol or an alcohol of formula
R
4
—CO—O—(R
5
CR
6
)—OH,
wherein:
R
4
denotes a C
1-8
-alkyl, C
5-7
-cycloalkyl, phenyl or phenyl-C
1-3
-alkyl group;
R
5
denotes a hydrogen atom, a C
1-3
-alkyl, C
5-7
-cycloalkyl, or phenyl group; and
R
6
denotes a hydrogen atom or a C
1-3
-alkyl group,
or the phrase “a group which may be cleaved in vivo from an imino or amino group” denotes for example a hydroxy group, an acyl group such as a benzoyl or pyridinoyl group or a C
1-16
-alkanoyl group such as the formyl, acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, an allyloxycarbonyl group, a C
1-16
-alkoxycarbonyl group such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert-butoxycarbonyl, pentoxycarbonyl, hexoxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl or hexadecyloxycarbonyl group, a phenyl-C
1-6
-alkoxycarbonyl group such as the benzyloxycarbonyl, phenylethoxycarbonyl or phenylpropoxycarbonyl group, a C
1-3
-alkylsulfonyl-C
2-4
-alkoxycarbonyl, C
1-3
-alkoxy-C
2-4
-alkoxy-C
2-4
-alkoxycarbonyl or R
4
CO—O—(R
5
CR
6
)—O—CO— group, wherein R
4
to R
6
are as hereinbefore defined.
Examples of preferred prodrug groups for a carboxy group include a C
1-6
-alkoxycarbonyl group such as the methoxycarbonyl, ethoxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxycarbonyl, n-pentyloxycarbonyl, n-hexyloxycarbonyl, or cyclohexyloxycarbonyl group or phenyl-C
1-3
-alkoxycarbonyl group such as the benzyloxycarbonyl group and
for an imino or amino group a C
1-9
-alkoxycarbonyl group such as the methoxycarbonyl, ethoxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxycarbonyl, n-pentyloxy-carbonyl, n-hexyloxycarbonyl, cyclohexyloxycarbonyl, n-heptyloxycarbonyl, n-octyloxycarbonyl or n-nonyloxycarbonyl group, a phenyl-C
1-3
-alkoxycarbonyl group such as the benzyloxycarbonyl group, a phenylcarbonyl group optionally substituted by a C
1-3
-alkyl group such as the benzoyl or 4-ethylbenzoyl group, a pyridinoyl group such as the nicotinoyl group, a C
1-3
-alkylsulfonyl-n-C
2-3
-alkoxycarbonyl or C
1-3
-alkoxy-C
2-3
-alkoxy-C
Hauel Norbert
Priepke Henning
Ries Uwe
Stassen Jean Marie
Wienen Wolfgang
Boehringer Ingelheim Pharma GmbH & Co. KG
Bottino Anthony P.
Morris Patricia L.
Raymond Robert P.
Witkowski Timothy X.
LandOfFree
Disubstituted bicyclic heterocycles, the preparation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Disubstituted bicyclic heterocycles, the preparation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Disubstituted bicyclic heterocycles, the preparation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3200312